Edition:
United States

NxStage Medical Inc (NXTM.O)

NXTM.O on Nasdaq

29.16USD
24 Feb 2017
Change (% chg)

$0.06 (+0.21%)
Prev Close
$29.10
Open
$29.04
Day's High
$29.30
Day's Low
$28.77
Volume
166,091
Avg. Vol
396,861
52-wk High
$29.99
52-wk Low
$13.49

Latest Key Developments (Source: Significant Developments)

NxStage Medical Inc raises FY 2015 guidance; gives Q4 2015 guidance
Tuesday, 3 Nov 2015 07:28am EST 

NxStage Medical Inc:Expects FY 2015 revenue to be between $332 and $333 million, versus its previously increased guidance for revenue to be at the high end of its range of $324 to $328 million.Now expects FY 2015 net loss to be between $15 and $16 million, versus its previous guidance of $18 to $20 million, which was revised from its original guidance of $20 to $24 million.For the Q4 2015, the Company expects revenue to be in a range of $86 and $87 million, and a net loss in the range of $2 to $3 million.FY 2015 revenue of $327.8 million and net loss of $(20.1) million - Thomson Reuters I/B/E/S.Q4 2015 revenue of $85.9 million and net loss of $(3.71) million - Thomson Reuters I/B/E/S.  Full Article

NxStage and Spindial announce partnership with Niguarda-Ca' Granda Hospital in Milan
Friday, 11 Sep 2015 07:00am EDT 

NxStage Medical Inc:Announces their new partnership with the Niguarda-Ca' Granda hospital in Milan, Italy to help assist hemodialysis patients, including both current NxStage patients and non-NxStage patients, who wish to travel to Milan.  Full Article

NxStage Medical Inc sees FY 2015 revenue guidance to achieve at high end of prior guidance, lowers net loss guidance; gives Q3 2015 revenue guidance above estimates, net loss guidance below estimates
Thursday, 6 Aug 2015 07:45am EDT 

NxStage Medical Inc:Expects Q3 2015 revenue to be between $82 million and $83 million.Q3 2015 net loss in the range of $4.5 million to $5.5 million.Net loss guidance reflects expectations for continued operating income from the Products Business offset by the Company's continued investment in NxStage Kidney Care.Q3 2015 revenue of $81.8 million and net loss of $5.9 million - Thomson Reuters I/B/E/S.Expects FY 2015 to achieve the top end of prior revenue guidance between $324 and $328 million.Now expects FY 2015 net loss guidance in a range of $18 to $20 million versus previous guidance of net loss in the range of $20 to $24 million.FY 2015 revenue of $327.6 million and net loss of $22.7 million - Thomson Reuters I/B/E/S.  Full Article

NxStage Medical Inc sees FY 2015 revenue trending towards high end of prior guidance; gives Q2 2015 guidance
Wednesday, 6 May 2015 07:59am EDT 

NxStage Medical Inc:Says it expects FY 2015 revenue trending towards the higher end of guidance range which was originally set to be between $324 million and $328 million.Expects Q2 2015 revenue to be between $79.0 million and $80.5 million and a net loss in the range of $5.5 million to $7.0 million.  Full Article

More From Around the Web

BRIEF-NxStage reports Q3 revenue $92 mln

* Says for fy company now expects revenue to be at high end of its previously increased guidance range of $360 to $365 million